McLaughlin Centre and The Centre for Applied Genomics, The Hospital for Sick Children, Toronto, ON M5G 1L7, Canada.
Hum Genet. 2011 Jul;130(1):123-48. doi: 10.1007/s00439-011-1037-2. Epub 2011 Jun 24.
Autism spectrum disorders (ASDs) are a group of conditions characterized by impairments in communication and reciprocal social interaction, and the presence of restricted and repetitive behaviors. The spectrum of autistic features is variable, with severity of symptoms ranging from mild to severe, sometimes with poor clinical outcomes. Twin and family studies indicate a strong genetic basis for ASD susceptibility. Recent progress in defining rare highly penetrant mutations and copy number variations as ASD risk factors has prompted early uptake of these research findings into clinical diagnostics, with microarrays becoming a 'standard of care' test for any ASD diagnostic work-up. The ever-changing landscape of the generation of genomic data coupled with the vast heterogeneity in cause and expression of ASDs (further influenced by issues of penetrance, variable expressivity, multigenic inheritance and ascertainment) creates complexity that demands careful consideration of how to apply this knowledge. Here, we discuss the scientific, ethical, policy and communication aspects of translating the new discoveries into clinical and diagnostic tools for promoting the well-being of individuals and families with ASDs.
自闭症谱系障碍(ASD)是一组以沟通和互惠社交互动障碍以及受限和重复行为为特征的疾病。自闭症特征的谱系是可变的,症状的严重程度从轻度到重度不等,有时临床结局不佳。双胞胎和家庭研究表明,ASD 易感性具有很强的遗传基础。最近在确定罕见的高外显率突变和拷贝数变异作为 ASD 风险因素方面取得的进展促使人们将这些研究发现尽早应用于临床诊断,微阵列成为任何 ASD 诊断工作的“标准护理”测试。基因组数据的不断变化的生成与 ASD 的病因和表达的巨大异质性(进一步受到外显率、可变表达性、多基因遗传和确定的影响)相结合,产生了复杂性,需要仔细考虑如何应用这些知识。在这里,我们讨论将新发现转化为临床和诊断工具以促进 ASD 个体和家庭福祉的科学、伦理、政策和沟通方面。